Browse Technologies

Displaying 1 - 4 of 4


Small Molecule mGlu3 NAMs as Therapeutics for CNS Disorders

The Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) has a mission to promote the translation of advances in basic science towards novel therapeutics. They have recruited faculty and staff with experience at over 10 different pharmaceutical companies to ensure a diverse set of approaches, techniques and philosophies to advancing compounds. Together they aim to de-risk drug discovery programs.


Licensing Contact

Mike Villalobos

615.322.6751
Therapeutics
Small Molecule

mGlu3 NAMs as Therapeutics for Chemoresistant Tumors

Targeting metabotropic glutamate receptor 3 (mGlu3) has been linked as a potential therapeutic to many neurological disorders and well as oncology through the use of dual specific mGlu2/3 Antagonists (LY341495, RO4491533, MGS0039, RO4988546).


Licensing Contact

Mike Villalobos

615.322.6751
Therapeutics
Small Molecule

Long-Lasting and Self-Sustaining Cell Therapy System

Researchers at Vanderbilt have created a novel drug delivery system using two distinct T-cell populations that interact to promote engraftment and persistence in pre-clinical models, increasing the efficacy of T-cell therapies. Furthermore, "booster" treatments can be administered months after the first dose to produce an expansion of antigen specific T cells. These advantages result in longer-term therapeutic efficacy and could reduce the number of treatments required. This system also represents a viable self-renewing platform for the delivery of biologic drugs in patients who would otherwise require frequent administration.


Licensing Contact

Cameron Sargent

615.322.5907

Use of Fluid Shear Stress Treatment to Enhance T Cell Activation

Researchers at Vanderbilt University have developed a technique to enhance immune cell activation by exposing cells to mechanical force while culturing. Proof-of-concept data indicate that activating immune cells with this method may improve therapeutic efficacy and reduce manufacturing expenses, making powerful CAR T cell therapies more accessible to patients in need.


Licensing Contact

Cameron Sargent

615.322.5907